Statistical flag only — not an accusation of fraud
This provider's $78.6M in total Medicare payments ranks in the 99th percentile of Clinical Laboratory providers nationally.
Medicare payments to this provider grew 2273% from 2015 to 2023.
66% of their billing comes from a single procedure code (K1034 — Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count).
This provider has been statistically flagged with a risk score of 71/100. Statistical flags are not accusations of fraud.
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 1574% in 2023
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2015 | $50.36 | $16.79 | 3.00x | $33.57 | $2.3M | 134.2K | 17 |
| 2016 | $1.5K | $132.22 | 11.64x | $1.4K | $1.1M | 8.7K | 7 |
| 2017 | $624.34 | $159.26 | 3.92x | $465.08 | $1.6M | 10.2K | 4 |
| 2018 | $612.69 | $233.84 | 2.62x | $378.85 | $2.6M | 10.9K | 5 |
| 2019 | $583.08 | $223.23 | 2.61x | $359.85 | $2.8M | 12.7K | 5 |
| 2020 | $255.04 | $111.78 | 2.28x | $143.26 | $6.7M | 59.5K | 12 |
| 2021 | $205.73 | $80.95 | 2.54x | $124.78 | $4.9M | 60.1K | 40 |
| 2022 | $110.28 | $45.61 | 2.42x | $64.67 | $3.2M | 70.0K | 77 |
| 2023 | $12.89 | $12.12 | 1.06x | $0.77 | $53.5M | 4.4M | 95 |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 4.3M | $51.1M | $11.76 | 1.02x |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 55.2K | $11.7M | $212.52 | 3.66x |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 71.5K | $6.3M | $88.68 | 2.26x |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 18.3K | $3.6M | $195.29 | 2.61x |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within | 26.6K | $661.9K | $24.90 | 2.01x |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 3.8K | $570.6K | $151.07 | 2.69x |
| G6056 | Opiate(s), drug and metabolites, each procedure | 20.2K | $525.2K | $25.95 | 2.45x |
| 87798 | Detection test by nucleic acid for organism, amplified probe technique | 13.7K | $472.4K | $34.47 | 1.05x |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 2.4K | $272.8K | $111.39 | 2.62x |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | 9.5K | $241.9K | $25.45 | 4.05x |
| G6052 | Meprobamate | 10.1K | $238.4K | $23.50 | 2.45x |
| 82542 | Chemical analysis using chromatography technique | 14.8K | $229.6K | $15.53 | 3.81x |
| G6031 | Benzodiazepines | 10.0K | $219.8K | $22.04 | 2.77x |
| 80299 | Quantitation of therapeutic drug | 10.0K | $182.6K | $18.27 | 2.79x |
| 87636 | Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19) and influenza virus types a and b | 1.2K | $167.7K | $141.42 | 2.12x |
| 80184 | Phenobarbital level | 9.8K | $150.0K | $15.27 | 3.72x |
| G6053 | Methadone | 10.2K | $128.5K | $12.65 | 4.23x |
| 80307 | Testing for presence of drug, by chemistry analyzers | 2.0K | $121.9K | $60.90 | 1.33x |
| 80053 | Blood test, comprehensive group of blood chemicals | 11.0K | $114.5K | $10.39 | 1.25x |
| G6045 | Dihydrocodeinone | 4.9K | $114.1K | $23.20 | 2.91x |
This provider submits charges 1.69 times higher than what Medicare actually pays.
A markup ratio of 1.69x means for every $100 Medicare pays, this provider initially charges $169. This is lower than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Clinical Laboratory providers in MI for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Vpa Pc | Troy, MI | $119.3M | ✓ Clear |
| Biotech Clinical Laboratories Inc | Novi, MI | $89.7M | ✓ Clear |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data